Please use this identifier to cite or link to this item:
Title: Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal Alzheimer’s disease trials: an AIBL study
Authors: Burnham, Samantha C;Raghavan, Nandini;Wilson, William;Baker, David;Ropacki, Michael T;Novak, Gerald;Ames, David;Ellis, Kathryn A;Martins, Ralph N;Maruff, Paul;Masters, Colin L;Romano, Gary;Rowe, Christopher C;Savage, Greg;Macaulay, S Lance;Narayan, Vaibhav A
Issue Date: 2015
EDate: 2015
Citation: Journal of Alzheimer's Disease 2015; 46(4): 1079-1089
Abstract: Background: There is a growing consensus that disease-modifying therapies must be given at the prodromal or preclinical stages of Alzheimer’s disease (AD) to be effective. A major unmet need is to develop and validate sensitive measures to track disease progression in these populations. Objective: To generate novel statistically-derived composites from standard scores, which have increased sensitivity in the assessment of change from baseline in prodromal AD. Methods: An empirically based method was employed to generate domain specific, global, and cognitive-functional novel composites. The novel composites were compared and contrasted with each other, as well as standard scores for their ability to track change from baseline. The longitudinal characteristics and power to detect decline of the measures were evaluated. Data from participants in the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study characterized as mild cognitively impaired with high neocortical amyloid-β burden were utilized for the study. Results: The best performing standard scores were CDR Sum-of-Boxes and MMSE. The statistically-derived novel composites performed better than the standard scores from which they were derived. The domain-specific composites generally did not perform as well as the global composites or the cognitive-functional composites. Conclusion: A systematic method was employed to generate novel statistically-derived composite measures from standard scores. Composites comprised of measures including function and multiple cognitive domains appeared to best capture change from baseline. These composites may be useful to assess progression or lack thereof in prodromal AD. However, the results should be replicated and validated using an independent clinical sample before implementation in a clinical trial.
DOI: 10.3233/JAD-143015
ORCID: 0000-0003-3910-2453
PubMed URL:
Type: Journal Article
Subjects: Alzheimer’s disease
Clinical marker
Mild cognitive impairment
Prodromal symptoms
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.